Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer

Abstract

Ad5/35 chimeric oncolytic viruses (OVs) have earlier been shown to increase the level of vector transduction, intratumoral virus spread and survival in a number of xenograft models when compared with Ad5-based viruses. Because radiation and chemotherapy are the current standards of care for most cancer indications, Ad5/35 OVs have been tested here in combination with either radiation or chemotherapy in a head and neck cancer (HNC) xenograft model to determine whether such combination therapies enhance the potency of the virus, thereby leading to a greater therapeutic effect. In mice treated with either Ad5 OV (OV-5) or Ad5/35 chimeric OV (OV-5T35H), there was a delay in tumor progression compared with animals treated with phosphate-buffered saline (PBS) alone. When Ad5/35 chimeric OV and radiation were used in combination, there was a further delay in tumor progression, which resulted in a significant increase in the mean survival time of tumor-bearing mice compared with Ad5/35 or Ad5 OV monotherapy or to the combination of Ad5 OV with radiation, which was significantly less potent (P<0.0001) compared with the Ad5/35 OV plus radiation combination. Similarly, a combination of Ad5/35 chimeric OV with cisplatin significantly delayed tumor progression compared with Ad5/35 OV or Ad5 OV virus alone or with the combination of Ad5 virus with cisplatin (P<0.01). In summary, the combination of the potent Ad5/35 chimeric OV with either radiation or chemotherapy leads to significantly increased survival of mice bearing highly aggressive tumors, and may therefore offer an effective treatment strategy for patients with difficult to treat HNC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477–4480.

    CAS  PubMed  Google Scholar 

  2. Khuri FR, Jain SR . Novel agents and incremental advances in the treatment of head and neck cancer. Semin Oncol 2004; 31: 3–10.

    Article  CAS  PubMed  Google Scholar 

  3. Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004; 114: 1871–1879.

    Article  CAS  PubMed  Google Scholar 

  4. Post DE, Khuri FR, Simons JW, Van Meir EG . Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933–946.

    Article  CAS  PubMed  Google Scholar 

  5. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.

    Article  CAS  PubMed  Google Scholar 

  6. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT . The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031–5036.

    CAS  PubMed  Google Scholar 

  7. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–330.

    CAS  PubMed  Google Scholar 

  8. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.

    Article  CAS  PubMed  Google Scholar 

  9. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738–5748.

    CAS  PubMed  Google Scholar 

  10. Graat HC, Wuisman PI, van Beusechem VW, Carette JE, Gerritsen WR, Bras J et al. Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses. Clin Cancer Res 2005; 11: 2445–2447; author reply 2447–2448.

    Article  CAS  PubMed  Google Scholar 

  11. Gaggar A, Shayakhmetov DM, Lieber A . CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408–1412.

    Article  CAS  PubMed  Google Scholar 

  12. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006; 80: 12109–12120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Reddy PS, Ganesh S, Yu DC . Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin Cancer Res 2006; 12: 2869–2878.

    Article  CAS  PubMed  Google Scholar 

  14. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490–1499.

    CAS  PubMed  Google Scholar 

  15. Chu RL, Post DE, Khuri FR, Van Meir EG . Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299–5312.

    Article  CAS  PubMed  Google Scholar 

  16. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517–525.

    CAS  PubMed  Google Scholar 

  17. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453–5460.

    CAS  PubMed  Google Scholar 

  18. Heise C, Lemmon M, Kirn D . Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 2000; 6: 4908–4914.

    CAS  PubMed  Google Scholar 

  19. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843–854.

    Article  PubMed  Google Scholar 

  20. Bernier J . Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nat Clin Pract Oncol 2005; 2: 305–314.

    Article  PubMed  Google Scholar 

  21. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007; 13: 7155–7165.

    Article  CAS  PubMed  Google Scholar 

  22. Zhang M, Li S, Li J, Ensminger WD, Lawrence TS . Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther 2003; 8: 21–28.

    Article  PubMed  Google Scholar 

  23. Forastiere AA, Trotti A, Pfister DG, Grandis JR . Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006; 24: 2603–2605.

    Article  PubMed  Google Scholar 

  24. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193–1196.

    CAS  PubMed  Google Scholar 

  25. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor—armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006; 12: 305–313.

    Article  CAS  PubMed  Google Scholar 

  26. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007; 67: 4399–4407.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank B Batiste, S Ulufatu, J Ho and T Langer from the animal facility and M Gebreyesus, P Janaswamy from cell culture group of Cell Genesys for their excellent work. We also thank Dr. Peter Working for critically reviewing the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Ganesh.

Additional information

Supplementary Information accompanies the paper on Cancer Gene Therapy website (http://www.nature.com/cgt)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganesh, S., Gonzalez-Edick, M., Gibbons, D. et al. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer Gene Ther 16, 383–392 (2009). https://doi.org/10.1038/cgt.2008.90

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2008.90

Keywords

This article is cited by

Search

Quick links